Drug Delivery Technologies: Players, products & prospects to 201

Pharma Business Daily
Claim your FREE trial subscription!

Pharmaceutical:

Drug Delivery Technologies: Players, products & prospects to 2015

Espicom Business Intelligence
Market Study November 2007

Providing...
Critical analyses and competitive ratings for major specialist developers
Unique sales forecasts to 2015 for key current and new products utilising drug delivery technologies
A comprehensive examination of the 4 major and compelling drug delivery sectors

While pharmaceutical sales have continued to rise steadily during the last five years generating over US$600 billion in 2006, the global drug delivery market has undergone rapid growth from an estimated US$26 billion in 2000 to approximately US$67 billion in 2006. This market has been driven by a number of factors including:

Patent expiration of leading brands forcing the pharmaceutical industry to evaluate ways to maximize product life-cycles through new formulations, combinations and repositioning;
Advances in new delivery technology (microencapsulation and nanotechnology); and
The development and cost-effective manufacture of new delivery materials (dendrimers, lipid formulations and biodegradable polymers).

Within this market there are a number of areas of advanced drug delivery which have attracted the attention of pharmaceutical industry and the investment community. The dramatic growth of the sector is reflected in the evolution of an array of delivery vehicles and hybrid platforms that are increasingly being used to deliver approved and novel therapeutic agents.
Focusing on the sectors that are driving growth!

VOLUME I
CONTROLLED- RELEASE DELIVERY

VOLUME II
NANO-ENABLED DELIVERY

VOLUME III
NUCLEIC ACID DELIVERY

VOLUME IV
TARGETED DELIVERY

Few sectors of the pharmaceutical industry will enjoy such a high level of growth in the future. Drug Delivery Technology: Assessing its potential

The time when advanced drug delivery was merely a means for profitable product life extension has gone. Drug delivery is now a major component of the pharmaceutical industry’s future and critical to bringing novel therapies to market.

Indeed, without the ability to effectively deliver targeted drugs in therapeutically significant quantities, many of the gene-based agents in research would not be viable. Despite the importance of the sector the pharmaceutical industry has not always been quick to embrace the full range of potential technologies and opportunities.

With so many companies pursuing a wide range of research strategies, it is difficult for industry and commercial executives to get a balanced and independent overview of the competitive landscape.

That is why this major new 4-volume report, Drug Delivery Technology: Players, products and prospects to 2015, is essential reading for everyone in the field, from niche technology specialists through to the investment community and the pharmaceutical industry itself.

By 2015 sales of products using drug delivery technology assessed in this report could exceed US$43 billion.

This report provides a detailed insight into the current and future market for drug delivery technology and...
Provides an overview of the marketplace, outlining current thinking on the technologies being researched and employed.
Appraises currently available products which utilise drug delivery technology and assesses their future.
Examines new product development among major specialist drug delivery companies, critically analysing the prospects at the product level and forecasting sales.
Allows ready comparison on different technologies within a company’s portfolio.
Provides a unique window on the sector’s product launch timetable
Includes detailed appendices which allow at-a-glance reviews of the competitive landscape for both new and up and coming products.

Use this report to...
Assess the strengths and weaknesses of competing products/technologies in the context of specific delivery sectors and development companies;
Identify and review licencing and collaboration partners;
Understand the merits and applications of the main approaches being researched; and, Quantify the commercial prospects for current and future products.

Unique company & technology evaluation

It is vital that management information is reliable, current and insightful. Today, product and company assessment must be seen in a wider competitive and market environment.

In this report we present a précis on each of the leading delivery specialists and potential new delivery platforms and have identified their key attributes, based on a number of criteria including:

Proprietary delivery technology;
Applications of the delivery technology within the pharma industry;
Management/technical expertise of the delivery specialist;
Competition within the delivery technology sector; and,
Products in development/approved utilising the delivery technology.

We have established a competitor ratio analysis based on each of the criteria mentioned above. Each criterion attracts an award of up to 10 points, with a maximum score of 50, thus enabling the establishment of an Espicom “ranking table” in each segment of the market, dependent on their relative attributes.

Multi-point evaluation and scoring assessment
Pharma drugs that utilise drug delivery systems have been evaluated based on a number of parameters, including:
The technology
Comparison of delivery platforms within each area including: activated, degradation or diffusion for controlled release systems; nano-engineered (nanocrystals, nanoparticle, nanosuspension) or nanocarriers (carbon/ceramic, dendrimer, liposome, micelle, polymeric nanoparticles) for nano-enabled delivery; viral or non-viral platforms for nucleic acid delivery and active or passive platforms for targeted delivery systems
The application of the technology within a number of therapy areas
Route of delivery (oral, parenteral, transdermal, implantable), delivery of small molecules/macromolecules and vaccines, additional features such as bioerodible materials etc
The current status of the technology in clinical development or following approval
Number of approved and marketed products, clinical or preclinical development candidates, single or multiple products
Competition within the technology arena
Alternative drug delivery systems to technologies under evaluation, advantages and disadvantages over competitors
The drug delivery specialist’s expertise
Number of drug delivery systems in development, strategic alliances, financial position, marketing presence
The product portfolio
Drug delivery systems under evaluation, products in development, commercialisation/developmental partnerships
Potential drug sales
Based on key events such as market, competition, patent expiry, time of entry into the market

Number of pages - 1904

For full details, please email keithw@cmsinfo.com

Order Form

CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: Jennifer Cowlard

For more information about us, visit CMSinfo.